FindTrial
Sign In

An open randomised study of the efficacy of standard radiotherapy with and without the addition of SRL172 (Mycobacterium vaccae) in the treatment of patients with small cell lung cancer (SIRON 13)

An open randomised study of the efficacy of standard radiotherapy with and without the addition of SRL172 (Mycobacterium vaccae) in the treatment of patients with small cell lung cancer (SIRON 13)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN22342362
Enrollment
Unknown
Registered
2002-08-19
Start date
2000-01-01
Completion date
Unknown
Last updated
2020-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung (small cell) Cancer Lung (small cell)

Interventions

1. Standard chemotherapy (as per protocol) 2. Standard chemotherapy + SRL172 injections (as per protocol)

Sponsors

UK Co-ordinating Committee for Cancer Research (UKCCCR)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients should be aged at least 18 years with histologically and/or cytologically confirmed unresectable small cell lung cancer, which includes limited or extensive stage disease 2. There should be presence of measurable or evaluable disease 3. Patients should be World Health Organisation (WHO) performance status 0-2 4. Serum creatinine 50 ml/min (if serum creatinine 120-140 micromol/l) if receiving cisplatin. If receiving carboplatin, creatinine clearance >20ml/min 5. Life expectance >3 months 6. Written informed consent

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026